References
- Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
- Gabizon A A, Lyass O, Berry G J, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22: 663–669
- Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
- Papahadjopoulos D, Allen T M, Gabizon A, Mayhew E, Matthay K, Huang S K, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–11464
- Martin F, Gabizon A. Human pharmacokinetics of stealth liposomes containing doxorubicin. J Cell Biochem 1992; 16E: 98
- North D. Tumour localization and safety of DOXIL (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. Proc Am Soc Clin Oncol 1993; 12: 51
- Bender R A, Anderson T, Fisher R I, Young R C. Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma. Am J Hematol 1978; 5: 203–209
- Dombernowsky P, Nissen N I, Larsen V. Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenylidene-D-glucopyranoside) (NSC- 122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 1972; 56: 71–82
- Gams R A, Bryan S, Dukart G, Weiss A, Case D, Jones S, et al. Mitoxantrone in malignant lymphoma. Invest New Drugs 1985; 3: 219–222
- Preti A, Cabanillas F. Management of recurrent or refractory lymphomas. The Non-Hodgkin's Lymphomas, I Magrath. Oxford University Press, London 1997; 415–722
- Tulpule A, Espina B M, Byron M, Berman N, Buchanan L, Boswell W, et al. Liposomal doxorubicin (TLC-D99) in combination with cyclophosphamide, vincristine, and prednisone is active in newly diagnosed aggressive non-Hodgkin's lymphoma. Blood 2001; 98: 346a
- Chanan-Khan A, Islam T, Bernstein S, Bernstein Z, Alam A, McCarthy P, et al. CDOP (Cyclophosphamide, Doxil, Vincristine, Prednisone) as a front-line regimen for elderly patients with intermediate grade non-Hodgkin's lymphoma. Blood 2001, 98(11 part 2):239b
- Di Bella N J, Khan M M, Dakhil S R, Logie K W, Marsland T A, Weinstein R E, et al. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study. Clin Lymphoma 2003; 3: 235–240
- Swain S M, Whaley F S, Ewer M S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–2879
- Hortobagyi G N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54(Suppl 4)1–7
- Pai V B, Nahata M C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263–302
- Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711–716
- Safra T, Muggia F, Jeffers S, Tsao-Wei D D, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029–1033